PL3201177T3 - Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi - Google Patents

Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi

Info

Publication number
PL3201177T3
PL3201177T3 PL15771593T PL15771593T PL3201177T3 PL 3201177 T3 PL3201177 T3 PL 3201177T3 PL 15771593 T PL15771593 T PL 15771593T PL 15771593 T PL15771593 T PL 15771593T PL 3201177 T3 PL3201177 T3 PL 3201177T3
Authority
PL
Poland
Prior art keywords
mono
viral replication
replication inhibitors
substituted indoles
dengue viral
Prior art date
Application number
PL15771593T
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Jean-François BONFANTI
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Dorothée Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54207512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3201177(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of PL3201177T3 publication Critical patent/PL3201177T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15771593T 2014-10-01 2015-09-30 Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi PL3201177T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14187373 2014-10-01
EP15156073 2015-02-23
PCT/EP2015/072534 WO2016050831A1 (en) 2014-10-01 2015-09-30 Mono- or di-substituted indoles as dengue viral replication inhibitors
EP15771593.9A EP3201177B1 (en) 2014-10-01 2015-09-30 Mono- or di-substituted indoles as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
PL3201177T3 true PL3201177T3 (pl) 2019-05-31

Family

ID=54207512

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15771593T PL3201177T3 (pl) 2014-10-01 2015-09-30 Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi

Country Status (31)

Country Link
US (1) US10206902B2 (pl)
EP (1) EP3201177B1 (pl)
JP (1) JP6701185B2 (pl)
KR (1) KR102478309B1 (pl)
CN (1) CN107001265B (pl)
AU (1) AU2015326920A1 (pl)
BR (1) BR112017006708A2 (pl)
CA (1) CA2958022A1 (pl)
CL (1) CL2017000742A1 (pl)
CY (1) CY1121972T1 (pl)
DK (1) DK3201177T3 (pl)
EA (1) EA033845B1 (pl)
ES (1) ES2711117T3 (pl)
HR (1) HRP20190139T1 (pl)
HU (1) HUE042628T2 (pl)
IL (1) IL251401A0 (pl)
LT (1) LT3201177T (pl)
MA (1) MA40769B1 (pl)
ME (1) ME03344B (pl)
MX (1) MX2017004298A (pl)
PH (1) PH12017500503A1 (pl)
PL (1) PL3201177T3 (pl)
PT (1) PT3201177T (pl)
RS (1) RS58394B1 (pl)
SG (1) SG11201702464WA (pl)
SI (1) SI3201177T1 (pl)
SM (1) SMT201900093T1 (pl)
TW (1) TW201619130A (pl)
UY (1) UY36339A (pl)
WO (1) WO2016050831A1 (pl)
ZA (1) ZA201702299B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
ES2761774T3 (es) 2014-10-01 2020-05-21 Merck Patent Gmbh Derivados del ácido borónico
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MA44498A (fr) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3436004B1 (en) * 2016-04-01 2024-12-11 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3630724T1 (sl) 2017-05-22 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CN114989131B (zh) * 2022-05-30 2023-10-24 云南大学 N’-(2-(苯并[1,3]二氧戊烷-5-基)酰基)芳酰肼类化合物及其合成和用途
WO2026057013A1 (zh) * 2024-09-14 2026-03-19 华武生物医药技术(湖北)有限责任公司 一类登革热病毒复制抑制剂、其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
KR20120123678A (ko) * 2010-01-15 2012-11-09 길리애드 사이언시즈, 인코포레이티드 플라비비리다에 바이러스의 억제제
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
PT3201176T (pt) * 2014-10-01 2019-03-04 Janssen Pharmaceuticals Inc Derivados indol mono- ou dissubstituídos como inibidores da replicação viral do dengue
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Also Published As

Publication number Publication date
AU2015326920A1 (en) 2017-03-02
KR20170063675A (ko) 2017-06-08
MX2017004298A (es) 2017-07-19
EP3201177A1 (en) 2017-08-09
UY36339A (es) 2016-04-01
PH12017500503A1 (en) 2017-08-30
US10206902B2 (en) 2019-02-19
JP6701185B2 (ja) 2020-05-27
CN107001265A (zh) 2017-08-01
JP2017531638A (ja) 2017-10-26
SMT201900093T1 (it) 2019-02-28
ME03344B (me) 2019-10-20
MA40769A (fr) 2017-09-09
CA2958022A1 (en) 2016-04-07
RS58394B1 (sr) 2019-04-30
PT3201177T (pt) 2019-02-12
US20170224658A1 (en) 2017-08-10
EP3201177B1 (en) 2018-11-21
CN107001265B (zh) 2021-06-15
BR112017006708A2 (pt) 2017-12-26
SI3201177T1 (sl) 2019-05-31
MA40769B1 (fr) 2019-03-29
ZA201702299B (en) 2018-12-19
EA201790700A1 (ru) 2017-08-31
DK3201177T3 (en) 2019-03-04
ES2711117T3 (es) 2019-04-30
TW201619130A (zh) 2016-06-01
LT3201177T (lt) 2019-03-12
KR102478309B1 (ko) 2022-12-15
WO2016050831A1 (en) 2016-04-07
HUE042628T2 (hu) 2019-07-29
CL2017000742A1 (es) 2017-11-03
IL251401A0 (en) 2017-05-29
HRP20190139T1 (hr) 2019-03-22
EA033845B1 (ru) 2019-12-02
CY1121972T1 (el) 2020-10-14
SG11201702464WA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
ZA202002435B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
ZA201702299B (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
ZA201702301B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
IL258043B (en) Mono- or di-converted indoles as inhibitors of dengue virus replication
ZA201801764B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
IL248550A0 (en) History of indolin-2-one or pyrrolo-pyridin-2-one
ZA201704783B (en) Indole derivatives as dengue viral replication inhibitors
IL284322B1 (en) Indolinone compounds and their uses
GB201402169D0 (en) Viral inhibitors
GB201416798D0 (en) Clamping arrangement
PT3095781T (pt) Composto de indol
PT3294738T (pt) Derivados mono ou di-substituídos de indol como inibidores da replicação viral da dengue
GB201507659D0 (en) Cutting arrangement